Brief: Kane Biotech Gets FDA Approval To Increase Dosage Allowance Of Revyve™ Antimicrobial Wound Gel
23/07/2024 13:32
July 23 (Reuters) - Kane Biotech Inc KNE.V :
* KANE BIOTECH RECEIVES FDA APPROVAL TO INCREASE DOSAGE
ALLOWANCE
OF ITS REVYVE™ ANTIMICROBIAL WOUND GEL
* KANE BIOTECH INC - FDA LIFTS USAGE LIMIT ON KANE BIOTECH'S
REVYVE™ GEL
Source text for Eikon: ID:nGNX7PHQd5
Further company coverage: KNE.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kane Biotech
See all newsBrief: Kane Biotech Announces FDA 510(K) Clearance For Revyve® Antimicrobial Skin And Wound Cleanser
Brief: Kane Biotech Restarts Commercial Activities And Strengthens North American Management
Brief: Kane Biotech Completes U.S. FDA 510(K) Submission For Revyve Antimicrobial Wound Cleanser
Brief: Kane Biotech Announces Second Quarter 2025 Financial Results
Brief: Kane Biotech provides further corporate update